US Federal Cannabis Reform Gains Momentum as Industry Stocks Surge

Democratic leaders in the United States have signaled that Congress now has enough votes to advance comprehensive federal cannabis legalization, moving the issue from speculation to a concrete legislative strategy. The shift follows a trend of record‑low federal marijuana prosecutions in 2025, reflecting the growing disconnect between federal prohibition and state‑level legalization.

At the same time, investors are focusing on the largest publicly traded cannabis companies in the United States and Canada. The AdvisorShares Pure US Cannabis ETF and the Global X Marijuana Life Sciences Index ETF together highlight firms such as Curaleaf Holdings, which operates dispensaries in 17 states, runs cultivation centers, and is expanding into Europe and the United Kingdom. The market outlook is shaped by ongoing federal rescheduling efforts that aim to move marijuana from Schedule I to Schedule III, a change that could unlock further growth for the sector.